Estrella Immunopharma, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells. Its current pipeline includes EB103 and EB104 for B-cell malignancies, along with EB201, which is being explored for systemic lupus erythematosus. Estrella Immunopharma operates in the advanced immunotherapy and cell therapy segment of the biopharmaceutical market, where it aims to address treatment challenges through engineered immune-based approaches. Headquartered in Emeryville, California, Estrella Immunopharma is positioned as a research-driven company developing next-generation therapies for oncology and autoimmune disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Cheng Liu Ph.D.
- Headquarters
- EmeryVille, CA, United States
- Website
- www.estrellabio.com